The state of emerging therapeutic company investment, deal-making, and pipeline

In the above video, David Thomas, BIO’s Vice President of Industry Analysis, provides an overview of recent investment and deal trends for emerging therapeutic companies, as well as an update on the rapidly changing Covid-19 R&D pipeline. The BIO Industry Analysis team has published the Covid Pipeline Tracker, and will soon publish annual investment and deal data. Data for the following areas are presented in this session: licensing, M&A, venture capital, IPOs, follow-on public offerings, and a new digital health deal breakdown of Clarivate data.